Stratified analysis of the association between anti-obesity medications and digestive adverse events: a real-world study based on the FDA adverse event reporting system database
Background Numerous digestive system adverse events (dsAEs) have been observed during the use of anti-obesity medications (AOMs), leading to concerns about the safety of these medications. However, most current studies are limited to the association of one class of drugs with specific digestive diso...
Saved in:
| Published in | BMC pharmacology & toxicology Vol. 25; no. 1; p. 64 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
12.09.2024
BioMed Central Ltd Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2050-6511 2050-6511 |
| DOI | 10.1186/s40360-024-00789-9 |
Cover
| Abstract | Background
Numerous digestive system adverse events (dsAEs) have been observed during the use of anti-obesity medications (AOMs), leading to concerns about the safety of these medications. However, most current studies are limited to the association of one class of drugs with specific digestive disorders, and there is no cascading analysis of AOMs in the digestive system. This study aims to use data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS) for a stratified analysis of the reported associations between AOMs and dsAEs.
Methods
We analyzed adverse event reports submitted to FAERS between January 2015 and December 2023 related to obesity treatment. It is important to note that FAERS data cannot establish causality or incidence rates. Pharmacovigilance (PV) signals were detected by disproportionate analyses through proportionate reporting ratio (PRR), reporting odds ratios (ROR), and information components (IC) to detect dsAEs associated with AOMs. Reporting rates, severity, and response outcomes of digestive adverse events were compared across AOMs by multivariate logistic regression analysis.
Results
Among 34,396 adverse events (AEs) related to obesity treatment, 8844 dsAEs were analyzed. Comparing with semaglutide and liraglutide, tirzepatide exhibited fewer reported dsAEs while semaglutide and liraglutide showed a high correlation with non-lethal pancreatitis reports. Bupropion-naltrexone (31.65%) reported the highest number of dsAEs, and a PV signal was detected in mouth and lips AEs (ROR = 2.97, 95% CI: 2.42–3.6). Orlistat (ROR = 3.30, 95% CI: 3.08–3.55) exhibited the highest association with gastrointestinal AEs compared to other AOMs. PV signal for hepatobiliary AEs (ROR = 6.13, 95% CI: 3.45–10.88) with phentermine-topiramate still needs further clarification.
Conclusions
Tirzepatide may be considered for patients with a history of digestive system disease or an elevated risk of pancreatitis based on the pattern of reported dsAEs. Caution is needed for the orofacial AEs when using bupropion-naltrexone. Orlistat has a higher reporting rate of gastrointestinal AEs, but these events are typically less severe. Phentermine-topiramate’s association with liver impairment requires further clinical investigation. This article provides insights into the reported associations between AOMs and dsAEs, which may aid clinicians in making more informed decisions about individualizing medication and managing potential adverse events. |
|---|---|
| AbstractList | Background
Numerous digestive system adverse events (dsAEs) have been observed during the use of anti-obesity medications (AOMs), leading to concerns about the safety of these medications. However, most current studies are limited to the association of one class of drugs with specific digestive disorders, and there is no cascading analysis of AOMs in the digestive system. This study aims to use data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS) for a stratified analysis of the reported associations between AOMs and dsAEs.
Methods
We analyzed adverse event reports submitted to FAERS between January 2015 and December 2023 related to obesity treatment. It is important to note that FAERS data cannot establish causality or incidence rates. Pharmacovigilance (PV) signals were detected by disproportionate analyses through proportionate reporting ratio (PRR), reporting odds ratios (ROR), and information components (IC) to detect dsAEs associated with AOMs. Reporting rates, severity, and response outcomes of digestive adverse events were compared across AOMs by multivariate logistic regression analysis.
Results
Among 34,396 adverse events (AEs) related to obesity treatment, 8844 dsAEs were analyzed. Comparing with semaglutide and liraglutide, tirzepatide exhibited fewer reported dsAEs while semaglutide and liraglutide showed a high correlation with non-lethal pancreatitis reports. Bupropion-naltrexone (31.65%) reported the highest number of dsAEs, and a PV signal was detected in mouth and lips AEs (ROR = 2.97, 95% CI: 2.42–3.6). Orlistat (ROR = 3.30, 95% CI: 3.08–3.55) exhibited the highest association with gastrointestinal AEs compared to other AOMs. PV signal for hepatobiliary AEs (ROR = 6.13, 95% CI: 3.45–10.88) with phentermine-topiramate still needs further clarification.
Conclusions
Tirzepatide may be considered for patients with a history of digestive system disease or an elevated risk of pancreatitis based on the pattern of reported dsAEs. Caution is needed for the orofacial AEs when using bupropion-naltrexone. Orlistat has a higher reporting rate of gastrointestinal AEs, but these events are typically less severe. Phentermine-topiramate’s association with liver impairment requires further clinical investigation. This article provides insights into the reported associations between AOMs and dsAEs, which may aid clinicians in making more informed decisions about individualizing medication and managing potential adverse events. BackgroundNumerous digestive system adverse events (dsAEs) have been observed during the use of anti-obesity medications (AOMs), leading to concerns about the safety of these medications. However, most current studies are limited to the association of one class of drugs with specific digestive disorders, and there is no cascading analysis of AOMs in the digestive system. This study aims to use data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS) for a stratified analysis of the reported associations between AOMs and dsAEs.MethodsWe analyzed adverse event reports submitted to FAERS between January 2015 and December 2023 related to obesity treatment. It is important to note that FAERS data cannot establish causality or incidence rates. Pharmacovigilance (PV) signals were detected by disproportionate analyses through proportionate reporting ratio (PRR), reporting odds ratios (ROR), and information components (IC) to detect dsAEs associated with AOMs. Reporting rates, severity, and response outcomes of digestive adverse events were compared across AOMs by multivariate logistic regression analysis.ResultsAmong 34,396 adverse events (AEs) related to obesity treatment, 8844 dsAEs were analyzed. Comparing with semaglutide and liraglutide, tirzepatide exhibited fewer reported dsAEs while semaglutide and liraglutide showed a high correlation with non-lethal pancreatitis reports. Bupropion-naltrexone (31.65%) reported the highest number of dsAEs, and a PV signal was detected in mouth and lips AEs (ROR = 2.97, 95% CI: 2.42–3.6). Orlistat (ROR = 3.30, 95% CI: 3.08–3.55) exhibited the highest association with gastrointestinal AEs compared to other AOMs. PV signal for hepatobiliary AEs (ROR = 6.13, 95% CI: 3.45–10.88) with phentermine-topiramate still needs further clarification.ConclusionsTirzepatide may be considered for patients with a history of digestive system disease or an elevated risk of pancreatitis based on the pattern of reported dsAEs. Caution is needed for the orofacial AEs when using bupropion-naltrexone. Orlistat has a higher reporting rate of gastrointestinal AEs, but these events are typically less severe. Phentermine-topiramate’s association with liver impairment requires further clinical investigation. This article provides insights into the reported associations between AOMs and dsAEs, which may aid clinicians in making more informed decisions about individualizing medication and managing potential adverse events. Background Numerous digestive system adverse events (dsAEs) have been observed during the use of anti-obesity medications (AOMs), leading to concerns about the safety of these medications. However, most current studies are limited to the association of one class of drugs with specific digestive disorders, and there is no cascading analysis of AOMs in the digestive system. This study aims to use data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS) for a stratified analysis of the reported associations between AOMs and dsAEs. Methods We analyzed adverse event reports submitted to FAERS between January 2015 and December 2023 related to obesity treatment. It is important to note that FAERS data cannot establish causality or incidence rates. Pharmacovigilance (PV) signals were detected by disproportionate analyses through proportionate reporting ratio (PRR), reporting odds ratios (ROR), and information components (IC) to detect dsAEs associated with AOMs. Reporting rates, severity, and response outcomes of digestive adverse events were compared across AOMs by multivariate logistic regression analysis. Results Among 34,396 adverse events (AEs) related to obesity treatment, 8844 dsAEs were analyzed. Comparing with semaglutide and liraglutide, tirzepatide exhibited fewer reported dsAEs while semaglutide and liraglutide showed a high correlation with non-lethal pancreatitis reports. Bupropion-naltrexone (31.65%) reported the highest number of dsAEs, and a PV signal was detected in mouth and lips AEs (ROR = 2.97, 95% CI: 2.42-3.6). Orlistat (ROR = 3.30, 95% CI: 3.08-3.55) exhibited the highest association with gastrointestinal AEs compared to other AOMs. PV signal for hepatobiliary AEs (ROR = 6.13, 95% CI: 3.45-10.88) with phentermine-topiramate still needs further clarification. Conclusions Tirzepatide may be considered for patients with a history of digestive system disease or an elevated risk of pancreatitis based on the pattern of reported dsAEs. Caution is needed for the orofacial AEs when using bupropion-naltrexone. Orlistat has a higher reporting rate of gastrointestinal AEs, but these events are typically less severe. Phentermine-topiramate's association with liver impairment requires further clinical investigation. This article provides insights into the reported associations between AOMs and dsAEs, which may aid clinicians in making more informed decisions about individualizing medication and managing potential adverse events. Keywords: Obesity, Anti-obesity medications, Digestive adverse events, Pharmacovigilance, Disproportionality analysis, FDA adverse event reporting system database Numerous digestive system adverse events (dsAEs) have been observed during the use of anti-obesity medications (AOMs), leading to concerns about the safety of these medications. However, most current studies are limited to the association of one class of drugs with specific digestive disorders, and there is no cascading analysis of AOMs in the digestive system. This study aims to use data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS) for a stratified analysis of the reported associations between AOMs and dsAEs. We analyzed adverse event reports submitted to FAERS between January 2015 and December 2023 related to obesity treatment. It is important to note that FAERS data cannot establish causality or incidence rates. Pharmacovigilance (PV) signals were detected by disproportionate analyses through proportionate reporting ratio (PRR), reporting odds ratios (ROR), and information components (IC) to detect dsAEs associated with AOMs. Reporting rates, severity, and response outcomes of digestive adverse events were compared across AOMs by multivariate logistic regression analysis. Among 34,396 adverse events (AEs) related to obesity treatment, 8844 dsAEs were analyzed. Comparing with semaglutide and liraglutide, tirzepatide exhibited fewer reported dsAEs while semaglutide and liraglutide showed a high correlation with non-lethal pancreatitis reports. Bupropion-naltrexone (31.65%) reported the highest number of dsAEs, and a PV signal was detected in mouth and lips AEs (ROR = 2.97, 95% CI: 2.42-3.6). Orlistat (ROR = 3.30, 95% CI: 3.08-3.55) exhibited the highest association with gastrointestinal AEs compared to other AOMs. PV signal for hepatobiliary AEs (ROR = 6.13, 95% CI: 3.45-10.88) with phentermine-topiramate still needs further clarification. Tirzepatide may be considered for patients with a history of digestive system disease or an elevated risk of pancreatitis based on the pattern of reported dsAEs. Caution is needed for the orofacial AEs when using bupropion-naltrexone. Orlistat has a higher reporting rate of gastrointestinal AEs, but these events are typically less severe. Phentermine-topiramate's association with liver impairment requires further clinical investigation. This article provides insights into the reported associations between AOMs and dsAEs, which may aid clinicians in making more informed decisions about individualizing medication and managing potential adverse events. Numerous digestive system adverse events (dsAEs) have been observed during the use of anti-obesity medications (AOMs), leading to concerns about the safety of these medications. However, most current studies are limited to the association of one class of drugs with specific digestive disorders, and there is no cascading analysis of AOMs in the digestive system. This study aims to use data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS) for a stratified analysis of the reported associations between AOMs and dsAEs. We analyzed adverse event reports submitted to FAERS between January 2015 and December 2023 related to obesity treatment. It is important to note that FAERS data cannot establish causality or incidence rates. Pharmacovigilance (PV) signals were detected by disproportionate analyses through proportionate reporting ratio (PRR), reporting odds ratios (ROR), and information components (IC) to detect dsAEs associated with AOMs. Reporting rates, severity, and response outcomes of digestive adverse events were compared across AOMs by multivariate logistic regression analysis. Among 34,396 adverse events (AEs) related to obesity treatment, 8844 dsAEs were analyzed. Comparing with semaglutide and liraglutide, tirzepatide exhibited fewer reported dsAEs while semaglutide and liraglutide showed a high correlation with non-lethal pancreatitis reports. Bupropion-naltrexone (31.65%) reported the highest number of dsAEs, and a PV signal was detected in mouth and lips AEs (ROR = 2.97, 95% CI: 2.42-3.6). Orlistat (ROR = 3.30, 95% CI: 3.08-3.55) exhibited the highest association with gastrointestinal AEs compared to other AOMs. PV signal for hepatobiliary AEs (ROR = 6.13, 95% CI: 3.45-10.88) with phentermine-topiramate still needs further clarification. Tirzepatide may be considered for patients with a history of digestive system disease or an elevated risk of pancreatitis based on the pattern of reported dsAEs. Caution is needed for the orofacial AEs when using bupropion-naltrexone. Orlistat has a higher reporting rate of gastrointestinal AEs, but these events are typically less severe. Phentermine-topiramate's association with liver impairment requires further clinical investigation. This article provides insights into the reported associations between AOMs and dsAEs, which may aid clinicians in making more informed decisions about individualizing medication and managing potential adverse events. Numerous digestive system adverse events (dsAEs) have been observed during the use of anti-obesity medications (AOMs), leading to concerns about the safety of these medications. However, most current studies are limited to the association of one class of drugs with specific digestive disorders, and there is no cascading analysis of AOMs in the digestive system. This study aims to use data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS) for a stratified analysis of the reported associations between AOMs and dsAEs.BACKGROUNDNumerous digestive system adverse events (dsAEs) have been observed during the use of anti-obesity medications (AOMs), leading to concerns about the safety of these medications. However, most current studies are limited to the association of one class of drugs with specific digestive disorders, and there is no cascading analysis of AOMs in the digestive system. This study aims to use data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS) for a stratified analysis of the reported associations between AOMs and dsAEs.We analyzed adverse event reports submitted to FAERS between January 2015 and December 2023 related to obesity treatment. It is important to note that FAERS data cannot establish causality or incidence rates. Pharmacovigilance (PV) signals were detected by disproportionate analyses through proportionate reporting ratio (PRR), reporting odds ratios (ROR), and information components (IC) to detect dsAEs associated with AOMs. Reporting rates, severity, and response outcomes of digestive adverse events were compared across AOMs by multivariate logistic regression analysis.METHODSWe analyzed adverse event reports submitted to FAERS between January 2015 and December 2023 related to obesity treatment. It is important to note that FAERS data cannot establish causality or incidence rates. Pharmacovigilance (PV) signals were detected by disproportionate analyses through proportionate reporting ratio (PRR), reporting odds ratios (ROR), and information components (IC) to detect dsAEs associated with AOMs. Reporting rates, severity, and response outcomes of digestive adverse events were compared across AOMs by multivariate logistic regression analysis.Among 34,396 adverse events (AEs) related to obesity treatment, 8844 dsAEs were analyzed. Comparing with semaglutide and liraglutide, tirzepatide exhibited fewer reported dsAEs while semaglutide and liraglutide showed a high correlation with non-lethal pancreatitis reports. Bupropion-naltrexone (31.65%) reported the highest number of dsAEs, and a PV signal was detected in mouth and lips AEs (ROR = 2.97, 95% CI: 2.42-3.6). Orlistat (ROR = 3.30, 95% CI: 3.08-3.55) exhibited the highest association with gastrointestinal AEs compared to other AOMs. PV signal for hepatobiliary AEs (ROR = 6.13, 95% CI: 3.45-10.88) with phentermine-topiramate still needs further clarification.RESULTSAmong 34,396 adverse events (AEs) related to obesity treatment, 8844 dsAEs were analyzed. Comparing with semaglutide and liraglutide, tirzepatide exhibited fewer reported dsAEs while semaglutide and liraglutide showed a high correlation with non-lethal pancreatitis reports. Bupropion-naltrexone (31.65%) reported the highest number of dsAEs, and a PV signal was detected in mouth and lips AEs (ROR = 2.97, 95% CI: 2.42-3.6). Orlistat (ROR = 3.30, 95% CI: 3.08-3.55) exhibited the highest association with gastrointestinal AEs compared to other AOMs. PV signal for hepatobiliary AEs (ROR = 6.13, 95% CI: 3.45-10.88) with phentermine-topiramate still needs further clarification.Tirzepatide may be considered for patients with a history of digestive system disease or an elevated risk of pancreatitis based on the pattern of reported dsAEs. Caution is needed for the orofacial AEs when using bupropion-naltrexone. Orlistat has a higher reporting rate of gastrointestinal AEs, but these events are typically less severe. Phentermine-topiramate's association with liver impairment requires further clinical investigation. This article provides insights into the reported associations between AOMs and dsAEs, which may aid clinicians in making more informed decisions about individualizing medication and managing potential adverse events.CONCLUSIONSTirzepatide may be considered for patients with a history of digestive system disease or an elevated risk of pancreatitis based on the pattern of reported dsAEs. Caution is needed for the orofacial AEs when using bupropion-naltrexone. Orlistat has a higher reporting rate of gastrointestinal AEs, but these events are typically less severe. Phentermine-topiramate's association with liver impairment requires further clinical investigation. This article provides insights into the reported associations between AOMs and dsAEs, which may aid clinicians in making more informed decisions about individualizing medication and managing potential adverse events. |
| ArticleNumber | 64 |
| Audience | General |
| Author | He, Qin-Qin Zhang, Shuyu Yang, Qing Wang, Junyan Wang, Menghuan |
| Author_xml | – sequence: 1 givenname: Qing surname: Yang fullname: Yang, Qing organization: Department of Anesthesiology, Huaihe Hospital of Henan University – sequence: 2 givenname: Junyan surname: Wang fullname: Wang, Junyan organization: Department of Anaesthesiology, Laboratory of Mitochondria and Metabolism, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University – sequence: 3 givenname: Menghuan surname: Wang fullname: Wang, Menghuan organization: Department of Anesthesiology, Huaihe Hospital of Henan University – sequence: 4 givenname: Shuyu surname: Zhang fullname: Zhang, Shuyu organization: Department of Anesthesiology, Huaihe Hospital of Henan University – sequence: 5 givenname: Qin-Qin surname: He fullname: He, Qin-Qin email: heqinqin2022@wchscu.cn organization: Department of Anaesthesiology, Laboratory of Mitochondria and Metabolism, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39267168$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNUstu1DAUjVARLaU_wAJZQkJsUpw4sR021ahQQKrEAlhbjn0z4yoTD7Yzo_ks_pA7D-hMhSqSRazc80jOuc-zk8EPkGUvC3pZFJK_ixVlnOa0rHJKhWzy5kl2VtKa5rwuipOD82l2EeMdxUsIKevyWXbKmpKLgsuz7Ne3FHRynQNL9KD7dXSR-I6kGRAdozcOp34gLaQVwICY5HLfQnRpTeZgndnOIw4ssW4KMbklUu0SQgQCSxhSfE80CaD7fOVDb0lMo12TVkf0ROmN1c2HyTEH8QsfkhumJK5jgjmxOukN50X2tNN9hIv98zz7cfPx-_Xn_Pbrpy_Xk9vc1IKlnPMWqK2kqDoQpTGyglZoCqJmnS1sxzXOJWMdra01Fa8aAZaVQpqaGV4V7DxjO91xWOj1Sve9WgQ312GtCqo2HahdBwo7UNsOVIOsqx1rMbYYj8FfCfqe6bVTx5PBzdTUL1GQNajJUOHtXiH4nyPmqeYuGuh7PYAfo2IFRduGsxqhrx9A7_wYsEVElbSoq7Iqm3vUVPeg3NB5NDYbUTWRVNacSi4QdfkPFN4W5s7g7nUO3x8R3hwQZlhvmkXfj9t1OAa-OozkbxZ_lhAB5Q5ggo8xQPd_QcsHJOPSdhfxu13_OHXfbESfYQrhPrZHWL8BSyITZg |
| CitedBy_id | crossref_primary_10_1016_j_soard_2025_01_007 crossref_primary_10_54022_shsv5n4_028 |
| Cites_doi | 10.1038/s41574-019-0176-8 10.1007/s11096-021-01330-2 10.1517/14656566.2015.1041505 10.2165/00003495-200666120-00012 10.3389/fendo.2023.1161521 10.1007/s13679-019-00350-4 10.1053/j.gastro.2011.02.018 10.1056/NEJMra1514009 10.1007/s40265-015-0427-5 10.3390/life10080138 10.1126/science.adn4691 10.1056/NEJMc2211120 10.1016/S0140-6736(11)60813-1 10.1016/S0140-6736(10)60888-4 10.1054/clnu.2002.0565 10.1016/j.eclinm.2023.101967 10.1097/AS9.0000000000000317 10.1208/s12248-007-9004-5 10.1111/dom.12593 10.1136/bmjgh-2022-009773 10.1007/s40264-024-01423-7 10.1159/000370038 10.1007/s40264-014-0163-x 10.1002/oby.20309 10.1016/S0140-6736(22)02403-5 10.1001/jama.2023.19574 10.1371/journal.pone.0160221 10.1111/obr.13543 10.7326/AITC201903050 10.1016/j.clgc.2023.07.003 10.1111/dom.14367 10.5530/jyp.2018.10.97 10.3390/healthcare10030420 10.1111/obr.13435 10.1053/j.gastro.2022.08.045 10.1001/jama.2020.12567 10.1016/j.bcp.2019.113669 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2024 2024. The Author(s). COPYRIGHT 2024 BioMed Central Ltd. 2024. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2024 2024 |
| Copyright_xml | – notice: The Author(s) 2024 – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 BioMed Central Ltd. – notice: 2024. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2024 2024 |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7U7 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR C1K CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM ADTOC UNPAY |
| DOI | 10.1186/s40360-024-00789-9 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Toxicology Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central Environmental Sciences and Pollution Management ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Toxicology Abstracts ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature Link url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository – sequence: 5 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 2050-6511 |
| ExternalDocumentID | 10.1186/s40360-024-00789-9 PMC11391863 A808560867 39267168 10_1186_s40360_024_00789_9 |
| Genre | Journal Article |
| GeographicLocations | United States United Kingdom United States--US |
| GeographicLocations_xml | – name: United States – name: United Kingdom – name: United States--US |
| GroupedDBID | 0R~ 53G 5VS 7X7 88E 8AO 8FI 8FJ AAFWJ AAJSJ AASML ABUWG ACGFS ACIHN ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS ASPBG BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU DIK EBD EBLON EBS EMB EMOBN FYUFA GROUPED_DOAJ GX1 HH5 HMCUK HYE IAO IHR IHW INH INR ITC KQ8 M1P M48 MK0 M~E OK1 PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SOJ SV3 UKHRP W2D AAYXX CITATION ALIPV CGR CUY CVF ECM EIF NPM 3V. 7U7 7XB 8FK AZQEC C1K DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 5PM ADTOC AHSBF EJD H13 UNPAY |
| ID | FETCH-LOGICAL-c573t-66be0d4874fe72cc84eb7a0e753fd1df6abe0833f05ddc46497ed3278c53c6413 |
| IEDL.DBID | M48 |
| ISSN | 2050-6511 |
| IngestDate | Sun Oct 26 03:47:12 EDT 2025 Tue Sep 30 17:07:46 EDT 2025 Thu Oct 02 12:05:06 EDT 2025 Thu Oct 09 21:52:55 EDT 2025 Mon Oct 20 22:49:33 EDT 2025 Mon Oct 20 17:01:20 EDT 2025 Thu May 22 21:24:06 EDT 2025 Sat Aug 09 01:32:18 EDT 2025 Wed Oct 01 03:13:00 EDT 2025 Thu Apr 24 22:57:28 EDT 2025 Sat Sep 06 07:27:25 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Obesity Digestive adverse events Anti-obesity medications Pharmacovigilance Disproportionality analysis FDA adverse event reporting system database |
| Language | English |
| License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c573t-66be0d4874fe72cc84eb7a0e753fd1df6abe0833f05ddc46497ed3278c53c6413 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://www.proquest.com/docview/3201542429?pq-origsite=%requestingapplication%&accountid=15518 |
| PMID | 39267168 |
| PQID | 3201542429 |
| PQPubID | 2028884 |
| ParticipantIDs | unpaywall_primary_10_1186_s40360_024_00789_9 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11391863 proquest_miscellaneous_3104039635 proquest_journals_3201542429 gale_infotracmisc_A808560867 gale_infotracacademiconefile_A808560867 gale_healthsolutions_A808560867 pubmed_primary_39267168 crossref_primary_10_1186_s40360_024_00789_9 crossref_citationtrail_10_1186_s40360_024_00789_9 springer_journals_10_1186_s40360_024_00789_9 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-09-12 |
| PublicationDateYYYYMMDD | 2024-09-12 |
| PublicationDate_xml | – month: 09 year: 2024 text: 2024-09-12 day: 12 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | BMC pharmacology & toxicology |
| PublicationTitleAbbrev | BMC Pharmacol Toxicol |
| PublicationTitleAlternate | BMC Pharmacol Toxicol |
| PublicationYear | 2024 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V |
| References | FL Greenway (789_CR38) 2010; 376 789_CR29 J Iqbal (789_CR23) 2022; 23 N Abdel-Wahab (789_CR44) 2016; 11 TJA Dekker (789_CR21) 2022; 387 789_CR26 Y Liu (789_CR28) 2023; 21 Phentermine-Topiramate. In (789_CR42) 2012 789_CR3 789_CR2 E Grunvald (789_CR16) 2022; 163 789_CR4 789_CR1 M Blüher (789_CR7) 2019; 15 R Ruze (789_CR12) 2023; 14 CM Apovian (789_CR39) 2013; 21 CM Perdomo (789_CR43) 2023; 401 K Suissa (789_CR15) 2021; 23 E Nolen-Doerr (789_CR17) 2019; 8 M Fusaroli (789_CR31) 2024; 47 G Frühbeck (789_CR10) 2014; 7 M Elashoff (789_CR37) 2011; 141 BA Swinburn (789_CR6) 2011; 378 MM Smits (789_CR36) 2016; 18 J Weaver (789_CR25) 2008; 10 789_CR13 N Alfaris (789_CR20) 2015; 16 OS Alkhezi (789_CR35) 2023; 24 789_CR32 SL Greig (789_CR19) 2015; 75 789_CR33 J Couzin-Frankel (789_CR34) 2023; 382 D Ryan (789_CR8) 2014; 22 B Sternby (789_CR40) 2002; 21 SB Heymsfield (789_CR5) 2017; 376 789_CR30 M Takada (789_CR27) 2014; 37 789_CR9 AG Tsai (789_CR11) 2019; 170 M Sodhi (789_CR22) 2023; 330 S Henness (789_CR18) 2006; 66 A Alsuhibani (789_CR24) 2022; 44 Y Chen (789_CR41) 2019; 170 DE Arterburn (789_CR14) 2020; 324 |
| References_xml | – volume: 15 start-page: 288 issue: 5 year: 2019 ident: 789_CR7 publication-title: Nat Reviews Endocrinol doi: 10.1038/s41574-019-0176-8 – volume: 44 start-page: 172 issue: 1 year: 2022 ident: 789_CR24 publication-title: Int J Clin Pharm doi: 10.1007/s11096-021-01330-2 – volume: 16 start-page: 1263 issue: 8 year: 2015 ident: 789_CR20 publication-title: Expert Opin Pharmacother doi: 10.1517/14656566.2015.1041505 – volume: 66 start-page: 1625 issue: 12 year: 2006 ident: 789_CR18 publication-title: Drugs doi: 10.2165/00003495-200666120-00012 – volume: 14 start-page: 1161521 year: 2023 ident: 789_CR12 publication-title: Front Endocrinol doi: 10.3389/fendo.2023.1161521 – volume: 8 start-page: 284 issue: 3 year: 2019 ident: 789_CR17 publication-title: Curr Obes Rep doi: 10.1007/s13679-019-00350-4 – volume: 141 start-page: 150 issue: 1 year: 2011 ident: 789_CR37 publication-title: Gastroenterology doi: 10.1053/j.gastro.2011.02.018 – volume: 376 start-page: 254 issue: 3 year: 2017 ident: 789_CR5 publication-title: N Engl J Med doi: 10.1056/NEJMra1514009 – volume: 75 start-page: 1269 issue: 11 year: 2015 ident: 789_CR19 publication-title: Drugs doi: 10.1007/s40265-015-0427-5 – ident: 789_CR30 doi: 10.3390/life10080138 – volume: 382 start-page: 1226 issue: 6676 year: 2023 ident: 789_CR34 publication-title: Sci (New York NY) doi: 10.1126/science.adn4691 – volume: 387 start-page: 1433 issue: 15 year: 2022 ident: 789_CR21 publication-title: N Engl J Med doi: 10.1056/NEJMc2211120 – volume: 378 start-page: 804 issue: 9793 year: 2011 ident: 789_CR6 publication-title: Lancet (London England) doi: 10.1016/S0140-6736(11)60813-1 – volume: 376 start-page: 595 issue: 9741 year: 2010 ident: 789_CR38 publication-title: Lancet (London England) doi: 10.1016/S0140-6736(10)60888-4 – volume: 21 start-page: 395 issue: 5 year: 2002 ident: 789_CR40 publication-title: Clin Nutr doi: 10.1054/clnu.2002.0565 – volume-title: LiverTox: clinical and Research Information on Drug-Induced Liver Injury year: 2012 ident: 789_CR42 – ident: 789_CR9 – ident: 789_CR26 doi: 10.1016/j.eclinm.2023.101967 – ident: 789_CR13 doi: 10.1097/AS9.0000000000000317 – volume: 10 start-page: 35 issue: 1 year: 2008 ident: 789_CR25 publication-title: AAPS J doi: 10.1208/s12248-007-9004-5 – volume: 18 start-page: 224 issue: 3 year: 2016 ident: 789_CR36 publication-title: Diabetes Obes Metab doi: 10.1111/dom.12593 – ident: 789_CR4 doi: 10.1136/bmjgh-2022-009773 – ident: 789_CR1 – ident: 789_CR3 – volume: 47 start-page: 585 issue: 6 year: 2024 ident: 789_CR31 publication-title: Drug Saf doi: 10.1007/s40264-024-01423-7 – ident: 789_CR29 – volume: 7 start-page: 408 issue: 6 year: 2014 ident: 789_CR10 publication-title: Obes Facts doi: 10.1159/000370038 – volume: 37 start-page: 421 issue: 6 year: 2014 ident: 789_CR27 publication-title: Drug Saf doi: 10.1007/s40264-014-0163-x – volume: 21 start-page: 935 issue: 5 year: 2013 ident: 789_CR39 publication-title: Obes (Silver Spring Md) doi: 10.1002/oby.20309 – volume: 401 start-page: 1116 issue: 10382 year: 2023 ident: 789_CR43 publication-title: Lancet (London England) doi: 10.1016/S0140-6736(22)02403-5 – volume: 330 start-page: 1795 issue: 18 year: 2023 ident: 789_CR22 publication-title: JAMA doi: 10.1001/jama.2023.19574 – volume: 11 start-page: e0160221 issue: 7 year: 2016 ident: 789_CR44 publication-title: PLoS ONE doi: 10.1371/journal.pone.0160221 – volume: 24 start-page: e13543 issue: 3 year: 2023 ident: 789_CR35 publication-title: Obes Rev Official J Int Assoc Study Obes doi: 10.1111/obr.13543 – volume: 170 start-page: Itc33 issue: 5 year: 2019 ident: 789_CR11 publication-title: Ann Intern Med doi: 10.7326/AITC201903050 – volume: 21 start-page: 594 issue: 5 year: 2023 ident: 789_CR28 publication-title: Clin Genitourin Cancer doi: 10.1016/j.clgc.2023.07.003 – volume: 23 start-page: 1542 issue: 7 year: 2021 ident: 789_CR15 publication-title: Diabetes Obes Metab doi: 10.1111/dom.14367 – ident: 789_CR32 doi: 10.5530/jyp.2018.10.97 – volume: 22 start-page: S1 issue: Suppl 2 year: 2014 ident: 789_CR8 publication-title: Obes (Silver Spring Md) – ident: 789_CR33 doi: 10.3390/healthcare10030420 – volume: 23 start-page: e13435 issue: 6 year: 2022 ident: 789_CR23 publication-title: Obes Reviews: Official J Int Association Study Obes doi: 10.1111/obr.13435 – volume: 163 start-page: 1198 issue: 5 year: 2022 ident: 789_CR16 publication-title: Gastroenterology doi: 10.1053/j.gastro.2022.08.045 – volume: 324 start-page: 879 issue: 9 year: 2020 ident: 789_CR14 publication-title: JAMA doi: 10.1001/jama.2020.12567 – volume: 170 start-page: 113669 year: 2019 ident: 789_CR41 publication-title: Biochem Pharmacol doi: 10.1016/j.bcp.2019.113669 – ident: 789_CR2 |
| SSID | ssj0000778852 |
| Score | 2.34184 |
| Snippet | Background
Numerous digestive system adverse events (dsAEs) have been observed during the use of anti-obesity medications (AOMs), leading to concerns about the... Numerous digestive system adverse events (dsAEs) have been observed during the use of anti-obesity medications (AOMs), leading to concerns about the safety of... Background Numerous digestive system adverse events (dsAEs) have been observed during the use of anti-obesity medications (AOMs), leading to concerns about the... BackgroundNumerous digestive system adverse events (dsAEs) have been observed during the use of anti-obesity medications (AOMs), leading to concerns about the... |
| SourceID | unpaywall pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 64 |
| SubjectTerms | Adolescent Adult Adverse Drug Reaction Reporting Systems - statistics & numerical data Adverse events Aged Analysis Anti-Obesity Agents - adverse effects Anti-Obesity Agents - therapeutic use Bayesian analysis Biomedical and Life Sciences Biomedicine Bupropion Clinical medicine Data base management systems Databases, Factual Diabetes Digestive system Digestive system diseases Digestive System Diseases - chemically induced Digestive System Diseases - epidemiology Drug therapy Drugs Enzymes FDA approval Female Gastrointestinal diseases Health services Humans Liraglutide Liraglutide - adverse effects Liraglutide - therapeutic use Male Medical errors Medical personnel Middle Aged Naltrexone Obesity Obesity - epidemiology Overweight Pancreatitis Pharmacology/Toxicology Pharmacovigilance Regression analysis Topiramate Type 2 diabetes United States - epidemiology United States Food and Drug Administration Weight control Weight reducing preparations Young Adult |
| SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELdG9wA8IL4JDDgkNB6oNTcfToKEUIFVExJVhTZpb5FjO6JSlXRrK9Q_i_-QO-ejyx4qnu-cxM75Pnzn3zH23hR5KoSJuDAYooR5rHkqgpz7I4vOboTunEsX_JzKs4vwx2V0ecCm7V0YKqtsdaJT1KbSdEZ-Evhk7dGgpF-WV5y6RlF2tW2hoZrWCuazgxi7ww59QsYasMOvp9PZr-7URcQY8kV-e3smkSerEHW44GiqOJnLlKc9C3VbT98wVLeLKLtM6n12d1Mu1faPWixuGKvJQ_ag8TJhXIvFI3Zgy8fseFbDVG-HcL67dbUawjHMdgDW2yfsr4OsnRfonYJqQEugKgB9RVC73wlNjRfyrOe8qjsMgEvW18eASDBgXAYLdSoo6v28suAwo1afQAE6rAvuMFvBwdwC2VQD-Gh61eT7uD8G6gQHzh5qAGqg-lYa85RdTE7Pv53xprUD11EcrLmUuRUGg6WwsLGvdRLaPFbCYvBUmJEppEJ6EgSFiIzRoQzT2JrAjxMdBVqi4X3GBmVV2hcMgtAW1EfLHykdRsokcSH8FJ-dh1YqP_LYqP2dmW5wz6n9xiJz8U8is1oEMhSBzIlAlnrsYzdmWaN-7OV-S1KS1TdXO5WRjRP0ZyXGjLHHPjgOUhr4bq2auw84A4Lf6nEe9Thxs-s-uZXErFE2q2y3NTz2riPTSCqgK221QR4Mu0WA2hbX43ktuN3M0EWWGDYnHkt6It0xEAR5n1LOfzso8hEGELgogceGrfTvvmvfig27HfIfC_xy_6xfsXu-27_U2OOIDdbXG_saXcV1_qbZ__8AJtVoOQ priority: 102 providerName: ProQuest – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Nb9QwELWgHIAD4ptAgUFC5cBaOLHjJNxWhVWFBOqhlXqzHNtRV1plK7IrtD-Lf8jYzmY3Farg7LGT2OOZNxn7DSHvbVNXjNmcMoshiqgLQyvGa5qlDsFujnAupAu-_5An5-LbRX7R0-T4uzD7-fu0lJ86gSaWUfQk1Huzila3yR10UjIkZuXx8D-FFRjM5dn2Xsxfu458z3ULvOeCrh-PHHKk98nddXulN7_0YrHnhmYPyYMeP8I0Lvgjcsu1j8nRaSSg3kzgbHefqpvAEZzuqKk3T8jvQEY7bxB3gu7pSGDZAKJA0LuFgv70Fsqs5nQZawdASMPHH3zYYMGG3BRaS9C-qnPnILBBdZ9BA0LRBQ1srBAIbMF7Sws4tH_U7Mt03Adi6gK_HiK1NPiTq77PU3I--3p2fEL7og3U5AVfUSlrxyyGQaJxRWZMKVxdaOYwLGpsahupsb3kvGG5tUZIURXO8qwoTc6NRJf6jBy0y9a9IMCFa3yFrCzVRuTalkXDsgrHroWTOssTkm6XU5me0dwX1lioENmUUkUVUKgCKqiAqhLycehzFfk8bpR-67VExTupgzFQ0xKRqsRosEjIhyDhzQE-2-j-VgN-gSfWGkkejiRxG5tx81YTVW9GOsUzD3ERReGbvBuafU9_NK51yzXKYEDNONpRnI_nUXGHL0PwKzEgLhNSjlR6EPDk4uOWdn4ZSMZTDA1wUnhCJlvt373XTTM2GXbIP0zwy_8b_RW5l4X97Et4HJKD1c-1e42gcFW_CdbgD4KyWqs priority: 102 providerName: Springer Nature – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lj9MwELagewAOvBcCCwwSWg7Ui_Owk3CrgGqFxKqHrbScIsd2REWVrkgrVP4V_5CxnaZNhVbL2eMkHtsz32Tsbwh5o6syZ0xzyjSGKEmZKpqzuKRRaBDscoRzLl3w9UycTpMvF_yipcmxd2F28_dhJt43CZpYRtGTUOvNcprfJAeCI-4ekIPp2WT0zVaPYxxjIIQOm1sx_-zY8zz79nfHAe0fjuwypHfIrVV9Kde_5Hy-44TG93w1o8ZxF9qzJz9OVsvyRP3eY3a83vjuk7stFoWRXzwPyA1TPyTHE09mvR7C-fZuVjOEY5hsaa7Xj8gfR2w7qxDDgmypTWBRASJKkNtJh_YkGMosZ3Th6xCAS-n7n4XYoEG7PBdaXpC2QnRjwDFLNR9AAsLaOXXMruDIcMF6Xg34aPuq8adRvw_4NAjqEjxNNdhTsLbPYzIdfz7_eErbAhBU8TReUiFKwzSGVEll0kipLDFlKpnBEKvSoa6ExPYsjivGtVaJSPLU6DhKM8VjJdA9H5JBvajNUwJxYipbbSsKpUq41FlasSjHZ5eJETLiAQk3i6NQLTu6LdIxL1yUlInCz1SBM1W4mSrygLzr-lx6bpArpV_ZNVf4-62dYSlGGaJegZFlGpC3TsKaFny3ku0NCRyBJenqSR71JNEkqH7zZl0XrUlqijiycBkRGX7J667Z9rTH7GqzWKEMBucsRpuM-njit0E3MgTSAoPrLCBZb4N0ApaovN9Sz747wvIQwwxUShyQ4WYvbb_rKo0Nu_12DQU_-z_x5-R25LadLQdyRAbLnyvzAgHmsnzZWpa_e6RycA priority: 102 providerName: Unpaywall |
| Title | Stratified analysis of the association between anti-obesity medications and digestive adverse events: a real-world study based on the FDA adverse event reporting system database |
| URI | https://link.springer.com/article/10.1186/s40360-024-00789-9 https://www.ncbi.nlm.nih.gov/pubmed/39267168 https://www.proquest.com/docview/3201542429 https://www.proquest.com/docview/3104039635 https://pubmed.ncbi.nlm.nih.gov/PMC11391863 https://doi.org/10.1186/s40360-024-00789-9 |
| UnpaywallVersion | publishedVersion |
| Volume | 25 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVFSB databaseName: Free Full-Text Journals in Chemistry customDbUrl: eissn: 2050-6511 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000778852 issn: 2050-6511 databaseCode: HH5 dateStart: 20120101 isFulltext: true titleUrlDefault: http://abc-chemistry.org/ providerName: ABC ChemistRy – providerCode: PRVADU databaseName: BioMed Central customDbUrl: eissn: 2050-6511 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000778852 issn: 2050-6511 databaseCode: RBZ dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 2050-6511 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000778852 issn: 2050-6511 databaseCode: KQ8 dateStart: 20120101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2050-6511 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000778852 issn: 2050-6511 databaseCode: DOA dateStart: 20120101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVBFR databaseName: Free Medical Journals - Free Access to All customDbUrl: eissn: 2050-6511 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000778852 issn: 2050-6511 databaseCode: DIK dateStart: 20120101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 2050-6511 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000778852 issn: 2050-6511 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2050-6511 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000778852 issn: 2050-6511 databaseCode: M~E dateStart: 20120101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 2050-6511 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000778852 issn: 2050-6511 databaseCode: RPM dateStart: 20120101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2050-6511 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000778852 issn: 2050-6511 databaseCode: 7X7 dateStart: 20150101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 2050-6511 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000778852 issn: 2050-6511 databaseCode: BENPR dateStart: 20150101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVFZP databaseName: Scholars Portal Open Access Journals customDbUrl: eissn: 2050-6511 dateEnd: 20250630 omitProxy: true ssIdentifier: ssj0000778852 issn: 2050-6511 databaseCode: M48 dateStart: 20120901 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal – providerCode: PRVAVX databaseName: HAS SpringerNature Open Access 2022 customDbUrl: eissn: 2050-6511 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000778852 issn: 2050-6511 databaseCode: AAJSJ dateStart: 20121201 isFulltext: true titleUrlDefault: https://www.springernature.com providerName: Springer Nature – providerCode: PRVAVX databaseName: Springer Nature Link customDbUrl: eissn: 2050-6511 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000778852 issn: 2050-6511 databaseCode: C6C dateStart: 20120112 isFulltext: true titleUrlDefault: http://www.springeropen.com/ providerName: Springer Nature |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1ba9swFBa9PGx9GLsvW5edwegeFm2KL5I9GCPNGsqgIZQGsr4YWZJpIDhdk7DlZ-0f7ki-pC6l20sg6Mi25HP5jiV9h5B3OktjxnRImcYUJUiFojHzU-p1DYLdEOGcWy44GfLjcfB9Ek62SFXuqJzAxa2pna0nNb6affz9c_0VDf6LM_iIf1oE6IYZxWhDbcSLabxNdjFSxbaUw0kJ951nFpjwuSI8Hgsxa0KwUZ2jufUyjVh102NfC1k3t1PWa6p75N4qv5TrX3I2uxa2Bg_JgxJvQq9QkEdky-SPycGoIKxed-Bsc_5q0YEDGG2orNdPyB9HXjvNEKeCLOlLYJ4BokaQmxcL5W4vlFlO6byoNQBu2b74IIgNGrRby0LvCtJWgV4YcOxRi88gAaHrjDr2VnCEt2Cjqwa8tL3V4Fuv2QeKpQ4cPRRU1GB3uto-T8l4cHTWP6ZlkQeqQuEvKeepYRrTpiAzwlMqCkwqJDOYRmW6qzMusT3y_YyFWquAB7Ew2vdEpEJfcQzBz8hOPs_NCwJ-YDJbUcvrShWEUkciY16M104Dw6UXtki3ep2JKhnQbSGOWeIyoYgnhQokqAKJU4EkbpEPdZ_Lgv_jTuk3VkuS4gxr7TySXoTIlmP2KFrkvZOwCo33VrI8BYEjsERcDcn9hiSavWo2V5qYVFaT-J6FxIi68Ene1s22p91Kl5v5CmUwAWc--l2cj-eF4tYjQ7DMMYGOWiRqqHQtYMnImy359MKRkncxlcBJ8VukU2n_5rnumrFObSH_McEv_znBr8h9z5mwrfKxT3aWVyvzGnHjMm2TbTERbbJ7eDQcneK_Pu-33TeYtnMT-Ht6eI7t4-Go9-MvD5ZvAA |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LbxMxEB6V9FA4IN4sFDpIUA7E6mbfi1ShQBultI0ilEq9bb22V0SKNoEkqvKz-AP8NsbeR7o9RFx69ti7tsfzsGe-AXgvszS2bekzW5KL4qWhYLHtpszpKDJ2fTLnzHPB-SDoX3jfL_3LLfhb5cLosMpKJhpBLadC35EfuI7W9qRQ4i-zX0xXjdKvq1UJDV6WVpCHBmKsTOw4VatrcuHmhydHtN8fHKd3PPrWZ2WVASb80F2wIEiVLclu9zIVOkJEnkpDbiuy4zPZkVnAqT1y3cz2pRRe4MWhkq4TRsJ3RUA6gMa9B9ueSw0t2P56PBj-qG957JBcTN-psnWi4GDukc6wGalGptVzzOKGRrytF24oxttBm_XL7QPYWeYzvrrmk8kN5dh7BA9Lqxa7BRs-hi2VP4H9YQGLvWrjaJ3lNW_jPg7XgNmrp_DHQOSOM7KGkZcgKTjNkGxT5Gv2wTKmjGgWYzYtKhqgCQ4orh2pQaI0L2Ykw5HrWtNzhQajav4ZOZKBPGEGIxYNrC5qHS6Rhtaf6h11m32weFCh2WMBeI06nlb3eQYXd7LJz6GVT3P1EtD1VKbrdjkdLjyfyyjMbCemsVNPBdzxLehU25mIEmddl_uYJMbfioKkYIGEWCAxLJDEFnyq-8wKlJGN1HuaS5IiU7YWUUk3Ivs5IB81tOCjodBCir4teJlrQTPQcF8Nyt0GJQkX0WyuODEphds8WR9FC97VzbqnDtjL1XRJNOTm2y5Jd1qPFwXj1jMjkzwgNz2yIGqwdE2gIc-bLfn4p4E-75DDQoviWtCuuH_9X5tWrF2fkP9Y4FebZ70HO_3R-VlydjI4fQ33HXOWdVGRXWgtfi_VGzJTF-nbUhYgXN21-PkHq4ml1w |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELdgSHw8IL7GCoMdEhoP1JqTOE7CW9VRja-pD5u0N8uxHVGpSivaauqfxX_I2U7TZkITPPvsxM75PnJ3vyPkvanKgjGTUmbQReFlpmnBkpLGkUVjN0VzzocLfpyLs0v-9Sq92qni99num5BkqGlwKE318mRuqnDFc3Gy4Ch4GUX9Qp2OK2hxl9zjqN1cD4OhGLZ_WViGLl4ab6pl_jq1o5FuyuUdxXQzabKNnD4iD1b1XK2v1XS6o5xGT8jjxqqEQWCDp-SOrZ-R43GApV734WJbZbXowzGMt4DV6-fkt4eonVRojYJqQEpgVgHahqC2nw-anC6kWU7oLHQUAB-cD7_9cMCA8RErlKGgXK_nhQWPEbX4BArQQJ1Sj9EKHtYWnA41gEu7R41OB905EAIauHsIgNPg8lndnBfkcvT5YnhGm1YOVKdZsqRClJYZdI54ZbNY65zbMlPMorNUmchUQuF4niQVS43RXPAisyaJs1yniRaoaPfJXj2r7QGBhNvK9c2KI6V5qkyeVSwucO2SW6HitEeizeeUusE5d-02ptL7O7mQgQUksoD0LCCLHvnYzpkHlI9bqY8cl8hQqdqKCDnI0X4V6CNmPfLBUzghgc_Wqql1wB04uK0O5WGHEi-37g5vOFE2wmUhk9gZvmhb4Zu8a4fdTJcwV9vZCmnQzWYJSlc8j5eBcdudoUks0E3OeyTvsHRL4CDHuyP15KeHHo_QYcBDSXqkv-H-7XvddmL99ob8wwG_-r_Vj8j98elIfv9y_u01eRj7q-16fBySveWvlX2DVuOyfOsFwx9KWGXh |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lj9MwELagewAOvBcCCwwSWg7Ui_Owk3CrgGqFxKqHrbScIsd2REWVrkgrVP4V_5CxnaZNhVbL2eMkHtsz32Tsbwh5o6syZ0xzyjSGKEmZKpqzuKRRaBDscoRzLl3w9UycTpMvF_yipcmxd2F28_dhJt43CZpYRtGTUOvNcprfJAeCI-4ekIPp2WT0zVaPYxxjIIQOm1sx_-zY8zz79nfHAe0fjuwypHfIrVV9Kde_5Hy-44TG93w1o8ZxF9qzJz9OVsvyRP3eY3a83vjuk7stFoWRXzwPyA1TPyTHE09mvR7C-fZuVjOEY5hsaa7Xj8gfR2w7qxDDgmypTWBRASJKkNtJh_YkGMosZ3Th6xCAS-n7n4XYoEG7PBdaXpC2QnRjwDFLNR9AAsLaOXXMruDIcMF6Xg34aPuq8adRvw_4NAjqEjxNNdhTsLbPYzIdfz7_eErbAhBU8TReUiFKwzSGVEll0kipLDFlKpnBEKvSoa6ExPYsjivGtVaJSPLU6DhKM8VjJdA9H5JBvajNUwJxYipbbSsKpUq41FlasSjHZ5eJETLiAQk3i6NQLTu6LdIxL1yUlInCz1SBM1W4mSrygLzr-lx6bpArpV_ZNVf4-62dYSlGGaJegZFlGpC3TsKaFny3ku0NCRyBJenqSR71JNEkqH7zZl0XrUlqijiycBkRGX7J667Z9rTH7GqzWKEMBucsRpuM-njit0E3MgTSAoPrLCBZb4N0ApaovN9Sz747wvIQwwxUShyQ4WYvbb_rKo0Nu_12DQU_-z_x5-R25LadLQdyRAbLnyvzAgHmsnzZWpa_e6RycA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Stratified+analysis+of+the+association+between+anti-obesity+medications+and+digestive+adverse+events%3A+a+real-world+study+based+on+the+FDA+adverse+event+reporting+system+database&rft.jtitle=BMC+pharmacology+%26+toxicology&rft.au=Wang%2C+Junyan&rft.au=Zhang%2C+Shuyu&rft.au=He%2C+Qin-Qin&rft.au=Wang%2C+Menghuan&rft.date=2024-09-12&rft.pub=BioMed+Central+Ltd&rft.issn=2050-6511&rft.eissn=2050-6511&rft.volume=25&rft.issue=1&rft_id=info:doi/10.1186%2Fs40360-024-00789-9&rft.externalDBID=n%2Fa&rft.externalDocID=A808560867 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2050-6511&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2050-6511&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2050-6511&client=summon |